The Department of Health and Human Services Office of Inspector General reported on March 19, 2026 that nursing homes recorded schizophrenia diagnoses for residents who were being given antipsychotic drugs, a coding step that removes those prescriptions from a publicly reported Medicare quality measure. The finding comes in an issue brief, OEI-02-23-00201, based on a review of 40 nursing home inspections that the Centers for Medicare and Medicaid Services carried out between 2018 and 2021, using surveyors' own observations, record reviews and interviews with staff, residents and family members. The brief states that nursing homes "inappropriately diagnosed schizophrenia to mask their misuse of antipsychotic drugs, artificially inflate their star rating, and skirt established safeguards," and that residents' care was compromised as a result. In one home, according to the report as quoted in coverage of it, a nurse practitioner added schizophrenia diagnoses to the records of dozens of residents given antipsychotic drugs on a single day. A companion brief, OEI-02-23-00200, released the same day, found the drugs given to manage dementia-related behaviour without non-drug approaches being tried first, and found that medical directors and consultant pharmacists did not act as required safeguards.

For a relative arriving to find their mother asleep in her wheelchair, the mechanics matter. Antipsychotics are not approved by the Food and Drug Administration to treat dementia, and the agency has warned they may increase the risk of death in seniors with dementia. Medicare's Care Compare rates each home in part on the share of long-stay residents receiving an antipsychotic, and that measure has excluded residents coded with schizophrenia, Huntington's disease or Tourette syndrome, as CMS set out when it announced audits of schizophrenia coding in January 2023. The OIG notes that schizophrenia is a serious mental illness whose symptoms usually appear in the teens or twenties, and that late-life onset is rare. Families, the brief found, were often not told that a diagnosis had been entered, and one of the OIG's three recommendations asks CMS to increase efforts to ensure residents and families are fully informed.

The sample was not random. The 40 inspections were surveys focused on dementia care or schizophrenia coding, and the OIG says plainly that they do not represent all nursing homes, while arguing the vulnerabilities they expose have wider implications. CMS did not explicitly concur or nonconcur with the three recommendations, and told the OIG that the findings come from compliance surveys already conducted and do not account for changes since, including continuing off-site audits of schizophrenia coding using resident assessment data. CMS had already re-specified the long-stay antipsychotic measure in a June 2025 memo, adding claims and encounter data to check both prescribing and the exclusion diagnoses; it took effect on Care Compare on October 29, 2025 and lifted the national figure for residents receiving an antipsychotic from 14.64 percent under the old measure to 16.98 percent under the new one. The American Health Care Association and National Center for Assisted Living, the largest provider group, has pointed to years of reductions in unnecessary antipsychotic use and to the clinical complexity of residents' needs.

Nothing in the report tells a family what any individual resident has or does not have, and nothing in it is a reason to change a medicine. What it does support is asking questions and expecting answers: which drug is being given and why, who made any diagnosis in the chart and on what basis, when the resident was last evaluated, and what non-drug approaches were tried. Those questions belong to the prescribing clinician and the facility, and the chart entry a family did not know about is a fair place to start.